

## Special Issue

# Novel Challenges and Advances in Pediatric Hematology and Hematologic Malignancies

### Message from the Guest Editor

Recent advancements have significantly improved diagnostics and therapies in pediatric hematology and hematologic malignancies. Immunotherapies, hematopoietic stem cell transplantation in nonmalignant and malignant hematological disorders, the introduction of long half-life coagulation products for patients with hemophilia, and many others have significantly changed the picture of pediatric hematology. However, there is a continuous need for further development in many fields of patient care to improve the prognosis and quality of life for children with hematologic disorders and malignancies. The Special Issue aims to highlight the latest advances in the clinical, genetic, and therapeutic aspects of children with hematologic disorders or malignancies to provide better information to further improve diagnosis and treatment.

### Guest Editor

Dr. Katarzyna Pawińska-Wasikowska

Department of Pediatric Oncology and Hematology, University Children's Hospital, Jagiellonian University Medical College, 31-008 Krakow, Poland

### Deadline for manuscript submissions

25 February 2026



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/212780](https://mdpi.com/si/212780)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/jpm)

[jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).